XERS earnings: a negative outcome, -19.5%

On March 6, 2024, Xeris Biopharma Holdings, Inc. reached its earnings. The result was a negative outcome, and the stock moved -19.5% in the window around the event. It had already run +28.7% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.